Accure Therapeutics awarded a total of $1.6M in grants from The Michael J. Fox Foundation and Fonds
Summary
The ACT-02 program is at an advanced preclinical stage, supported by comprehensive positive efficacy data in Parkinsons in vivo models and a GLP (Good Laboratory Practice) toxicology and safety pharmacology data set.This is a major milestone for the company, demonstrating support for the robust science and R&D plans behind ACT-02 and its potential in addressing critical unmet needs in PD.An MJFF grant to fund the phase I IND study in 2026Accure Therapeutics received a $1.12M grant from The Michael J. This project is a collaboration between the Institute of Pharmacology, Toxicology and Pharmacy at Stiftung Tier\xe4rztliche Hochschule Hannover, led by Prof. Dr. Franziska Richter Assencio, and Accure Therapeutics.Funding will be used to finalize the preclinical activities required for completing investigational new drug (IND) studies, with a view to filing an application for a phase I IND study in 2026.Our team is extremely keen to further study ACT-02 which has already demonstrated neuroprotective effects in dopaminergic neurons, reduction of -synuclein aggregation and neuroinflammation, while improving mitochondrial functioning and enhancing the motor and cognitive performance in Thy1-aSyn mice (line 61) experiments, said Prof. Dr. Franziska Richter Assencio.An FNR grant to support a public-private partnership on Parkinsons diseaseThe FNR BRIDGES program, managed by the Luxembourg National Research Fund (FNR), provides financial support for industry partnerships between public research institutions in Luxembourg and national or international companies, aiming to stimulate innovation and sustainable value creation.The 0.48m grant (including monetary and in-kind subsidies) will support the Transcend-PD project: Pharmacological targeting of Prolyl Endopeptidase in human induced pluripotent stem cells-derived neurons for the development of precision medicine therapeutic strategies in Parkinsons disease. It aims to assess the efficacy of ACT-02 in highly translational patient derived induced pluripotent stem cell (iPSC) models of PD, to enhance patient selection and stratification for future precision medicine strategies.This public-private collaboration will allow us to get more insights into first causative treatments for Parkinsons disease by further describing the effect of modulating a new target, PREP, with a new orally active drug candidate, said Prof. Rejko Kr\xfcger. These two grants are significant steps forward for us and our academic partners in the development of our first-in-class drug candidate, ACT-02, for Parkinsons disease, said Laurent Nguyen, co-founder and CEO at Accure Therapeutics. It has a unique portfolio of three first-in-class new chemical entities programs, pursuing innovative targets and potential game changers in the treatment of serious diseases of the central nervous system: ACT-01 (licensed to Oculis NASDAQ: OCS) at positive phase II clinical trial completed stage in acute optic neuritis, ACT-02 at IND-enabling stage in Parkinsons disease and ACT-03 at CCS-stage in epilepsy.With an experienced business and scientific team, Accure Therapeutics is one of the few companies that operate in an agnostic fashion on initial science to deliver cutting-edge drugs in CNS.